title: Autologous transfusion and other approaches to reduce allogeneic blood exposure.
abstract: When used as the sole source of transfused blood, the principal advantage of autologous blood transfusion is the avoidance of transmission of infectious agents and the avoidance of the purported adverse immunomodulatory effects of allogeneic transfusion. In the 1990s, however, the risks of transfusion-transmitted diseases have been greatly reduced, and estimates of the cost-effectiveness of pre-operative autologous blood donations now vary between 2470 dollars and 3,400,000 dollars per quality-adjusted year of life saved, depending on assumptions about the existence and magnitude of any adverse immunomodulatory effects of allogeneic transfusion. There is a paucity of randomized controlled trials evaluating the clinical outcomes and the cost-effectiveness of autologous transfusion procedures, and this situation is unlikely to change in the near future because of the difficulties in conducting such trials. This chapter reviews the available evidence on the efficacy, safety and cost-effectiveness of the three common autologous transfusion procedures, that is, pre-operative autologous blood donation, acute normovolaemic haemodilution, and intra-operative and post-operative blood recovery.
authors: Blood Bank and Transfusion Service, New York University Medical Center.New York, USA.
authors: E C
authors: EC
authors: Vamvakas
authors: A A
authors: AA
authors: Pineda
mesh_terms: D001782:Blood Donors; D001787:Blood Group Incompatibility / Q000517:prevention & control; D001800:Blood Specimen Collection; D001804:Blood Transfusion, Autologous / Q000191:economics; D003362:Cost-Benefit Analysis; D004921:Erythropoietin / Q000627:therapeutic use; D006438:Hemodilution; D006801:Humans; D007239:Infections / Q000635:transmission; D007432:Intraoperative Period; D011300:Preoperative Care; D011994:Recombinant Proteins
chemical_list: D011994:Recombinant Proteins; D004921:Erythropoietin